Population dynamics and the evolution of antifungal drug resistance in Candida albicans

FEMS Microbiology Letters

Volumn 333, Issue 2, 2012, Pages 85-93

  Huang, Mian ^a   Kao, Katy C ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Candida albicans; Drug resistance; Evolution; Population dynamics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; FLUCONAZOLE;

ANTIFUNGAL RESISTANCE; CANDIDA ALBICANS; CARBON SOURCE; CHROMOSOME REARRANGEMENT; CONCENTRATION RESPONSE; DRUG EXPOSURE; DRUG SENSITIVITY; EVOLUTIONARY ADAPTATION; FUNGAL COMMUNITY; FUNGAL VIRULENCE; FUNGUS GROWTH; FUNGUS ISOLATION; FUNGUS MUTANT; GENE MUTATION; GENE TRANSFER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOLECULAR EVOLUTION; NONHUMAN; POPULATION DISTRIBUTION; POPULATION DYNAMICS; POPULATION SIZE; POPULATION STRUCTURE; PRIORITY JOURNAL; REPRODUCTION; REPRODUCTIVE FITNESS; SHORT SURVEY;

ADAPTATION, BIOLOGICAL; ALLELES; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL; EVOLUTION, MOLECULAR; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; MUTATION; TIME FACTORS;

CANDIDA; CANDIDA ALBICANS;

EID: 84864136389     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1111/j.1574-6968.2012.02587.x     Document Type: Short Survey

References (64)

1. Anderson JB, Sirjusingh C, Parsons AB, Boone C, Wickens C, Cowen LE & Kohn LM (2003) Mode of selection and experimental evolution of antifungal drug resistance in Saccharomyces cerevisiae. Genetics 163: 1287-1298.
2. Andersson DI (2003) Persistence of antibiotic resistant bacteria. Curr Opin Microbiol 6: 452-456.
3. Andersson DI & Hughes D (2010) Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8: 260-271.
4. Andes D, Forrest A, Lepak A, Nett J, Marchillo K & Lincoln L (2006) Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob Agents Chemother 50: 2374-2383.
5. Bachtrog D & Gordo I (2004) Adaptive evolution of asexual populations under Muller's ratchet. Evolution 58: 1403-1413.
6. Beck-Sague C & Jarvis WR (1993) Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 167: 1247-1251.
7. Bennett RJ & Johnson AD (2003) Completion of a parasexual cycle in Candida albicans by induced chromosome loss in tetraploid strains. EMBO J 22: 2505-2515.
8. Bjorkman J, Hughes D & Andersson DI (1998) Virulence of antibiotic-resistant Salmonella typhimurium. P Natl Acad Sci USA 95: 3949-3953.
9. Bjorkman J, Samuelsson P, Andersson DI & Hughes D (1999) Novel ribosomal mutations affecting translational accuracy, antibiotic resistance and virulence of Salmonella typhimurium. Mol Microbiol 31: 53-58.
10. Blaser J, Stone BB, Groner MC & Zinner SH (1987) Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 31: 1054-1060.
11. Campos PR & de Oliveira VM (2004) Mutational effects on the clonal interference phenomenon. Evolution 58: 932-937.
12. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T & Ghannoum MA (2001) Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 183: 5385-5394.
13. Chapeland-Leclerc F, Hennequin C, Papon N, Noël T, Girard A, Socié G, Ribaud P & Lacroix C (2010) Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother 54: 1360-1362.
14. Coste A, Turner V, Ischer F et al. (2006) A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172: 2139-2156.
15. Cowen LE, Sanglard D, Calabrese D, Sirjusingh C, Anderson JB & Kohn LM (2000) Evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol 182: 1515-1522.
16. Cowen LE, Kohn LM & Anderson JB (2001) Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol 183: 2971-2978.
17. Cowen LE, Nantel A, Whiteway MS, Thomas DY, Tessier DC, Kohn LM & Anderson JB (2002) Population genomics of drug resistance in Candida albicans. P Natl Acad Sci USA 99: 9284-9289.
18. Desai MM & Fisher DS (2007) Beneficial mutation selection balance and the effect of linkage on positive selection. Genetics 176: 1759-1798.
19. Desai MM, Fisher DS & Murray AW (2007) The speed of evolution and maintenance of variation in asexual populations. Curr Biol 17: 385-394.
20. Dettman JR, Rodrigue N, Melnyk AH, Wong A, Bailey SF & Kassen R (2012) Evolutionary insight from whole-genome sequencing of experimentally evolved microbes. Mol Ecol 21: 2058-2077.
21. Elena SF & Lenski RE (2003) Evolution experiments with microorganisms: the dynamics and genetic bases of adaptation. Nat Rev Genet 4: 457-469.
22. Gerrish P (2001) The rhythm of microbial adaptation. Nature 413: 299-302.
23. Gerrish PJ & Lenski RE (1998) The fate of competing beneficial mutations in an asexual population. Genetica 102-103: 127-144.
24. Huang M, McClellan M, Berman J & Kao KC (2011) Evolutionary dynamics of Candida albicans during in vitro evolution. Eukaryot Cell 10: 1413-1421.
25. Hull CM & Johnson AD (1999) Identification of a mating type-like locus in the asexual pathogenic yeast Candida albicans. Science 285: 1271-1275.
26. Johanson U, Aevarsson A, Liljas A & Hughes D (1996) The dynamic structure of EF-G studied by fusidic acid resistance and internal revertants. J Mol Biol 258: 420-432.
27. Kanafani ZA & Perfect JR (2008) Resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 46: 120-128.
28. Kao KC & Sherlock G (2008) Molecular characterization of clonal interference during adaptive evolution in asexual populations of Saccharomyces cerevisiae. Nat Genet 40: 1499-1504.
29. Katiyar S, Pfaller M & Edlind T (2006) Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother 50: 2892-2894.
30. Kelly SL, Lamb DC, Kelly DE, Loeffler J & Einsele H (1996) Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 348: 1523-1524.
31. Kim Y & Stephan W (2003) Selective sweeps in the presence of interference among partially linked loci. Genetics 164: 389-398.
32. Lai CC, Tan CK, Huang YT, Shao PL & Hsueh PR (2008) Current challenges in the management of invasive fungal infections. J Infect Chemother 14: 77-85.
33. Lamb DC, Kelly DE, White TC & Kelly SL (2000) The R467K amino acid substitution in Candida albicans sterol 14alpha-demethylase causes drug resistance through reduced affinity. Antimicrob Agents Chemother 44: 63-67.
34. Loffler J, Kelly SL, Hebart H, Schumacher U, Lass-Florl C & Einsele H (1997) Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett 151: 263-268.
35. Loffler J, Einsele H, Hebart H, Schumacher U, Hrastnik C & Daum G (2000) Phospholipid and sterol analysis of plasma membranes of azole-resistant Candida albicans strains. FEMS Microbiol Lett 185: 59-63.
36. Marr KA, White TC, van Burik JA & Bowden RA (1997) Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 25: 908-910.
37. Marr KA, Lyons CN, Rustad TR, Bowden RA & White TC (1998) Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother 42: 2584-2589.
38. Miller LG, Hajjeh RA & Edwards JE Jr. (2001) Estimating the cost of nosocomial candidemia in the united states. Clin Infect Dis 32: 1110.
39. Nolte FS, Parkinson T, Falconer DJ et al. (1997) Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 41: 196-199.
40. Olaiya AF & Sogin SJ (1979) Ploidy determination of Canadida albicans. J Bacteriol 140: 1043-1049.
41. Orr HA (2000) The rate of adaptation in asexuals. Genetics 155: 961-968.
42. Park S, Kelly R, Kahn JN et al. (2005) Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 49: 3264-3273.
43. Pfaller MA (2012) Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 125: S3-S13.
44. Pfaller MA & Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133-163.
45. Pfaller MA & Diekema DJ (2010) Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36: 1-53.
46. Pfaller MA, Diekema DJ, Gibbs DL et al. (2010) Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 48: 1366-1377.
47. Riggsby WS, Torres-Bauza LJ, Wills JW & Townes TM (1982) DNA content, kinetic complexity, and the ploidy question in Candida albicans. Mol Cell Biol 2: 853-862.
48. Sandegren L, Lindqvist A, Kahlmeter G & Andersson DI (2008) Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli. J Antimicrob Chemother 62: 495-503.
49. Sanglard D & Odds FC (2002) Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2: 73-85.
50. Sanglard D, Ischer F, Monod M & Bille J (1997) Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143(Pt 2): 405-416.
51. Schrag SJ & Perrot V (1996) Reducing antibiotic resistance. Nature 381: 120-121.
52. Schrag SJ, Perrot V & Levin BR (1997) Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc Biol Sci 264: 1287-1291.
53. Selmecki A, Forche A & Berman J (2006) Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313: 367-370.
54. Selmecki A, Gerami-Nejad M, Paulson C, Forche A & Berman J (2008) An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol Microbiol 68: 624-641.
55. Selmecki AM, Dulmage K, Cowen LE, Anderson JB & Berman J (2009) Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLoS Genet 5: e1000705.
56. Selmecki A, Forche A & Berman J (2010) Genomic plasticity of the human fungal pathogen Candida albicans. Eukaryot Cell 9: 991-1008.
57. Shaver AC, Dombrowski PG, Sweeney JY, Treis T, Zappala RM & Sniegowski PD (2002) Fitness evolution and the rise of mutator alleles in experimental Escherichia coli populations. Genetics 162: 557-566.
58. White TC (1997) Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41: 1482-1487.
59. White TC, Holleman S, Dy F, Mirels LF & Stevens DA (2002) Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 46: 1704-1713.
60. Wilke CO (2004) The speed of adaptation in large asexual populations. Genetics 167: 2045-2053.
61. Wirsching S, Michel S & Morschhauser J (2000) Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Mol Microbiol 36: 856-865.
62. Wirsching S, Moran GP, Sullivan DJ, Coleman DC & Morschhauser J (2001) MDR1-mediated drug resistance in Candida dubliniensis. Antimicrob Agents Chemother 45: 3416-3421.
63. Yedid G & Bell G (2001) Microevolution in an electronic microcosm. Am Nat 157: 465-487.
64. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ & Feudtner C (2005) The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41: 1232-1239.